Jefferies raised the firm's price target on Surgery Partners to $17 from $15 and keeps a Buy rating on the shares. The firm says the company had a good Q1, particularly given the weather-related headwinds that affected most health-care services providers. Payor mix issues that emerged last quarter moderated in Q1 and should gradually improve over the course of the year, Jefferies argues.
